Glaukos Corporation (GKOS) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. raised its holdings in Glaukos Corporation (NYSE:GKOS) by 3.4% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,668,345 shares of the medical instruments supplier’s stock after buying an additional 55,507 shares during the period. Vanguard Group Inc. owned about 4.85% of Glaukos Corporation worth $69,187,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in GKOS. Alliancebernstein L.P. raised its stake in Glaukos Corporation by 26.7% in the second quarter. Alliancebernstein L.P. now owns 1,636,621 shares of the medical instruments supplier’s stock valued at $67,871,000 after buying an additional 344,739 shares during the period. Peregrine Capital Management LLC bought a new stake in Glaukos Corporation in the second quarter valued at approximately $13,645,000. Wells Fargo & Company MN raised its stake in Glaukos Corporation by 22.9% in the second quarter. Wells Fargo & Company MN now owns 1,421,990 shares of the medical instruments supplier’s stock valued at $58,971,000 after buying an additional 265,428 shares during the period. Redwood Investments LLC bought a new stake in Glaukos Corporation in the second quarter valued at approximately $6,756,000. Finally, Old Mutual Global Investors UK Ltd. raised its stake in Glaukos Corporation by 247.9% in the second quarter. Old Mutual Global Investors UK Ltd. now owns 213,445 shares of the medical instruments supplier’s stock valued at $8,851,000 after buying an additional 152,089 shares during the period.

GKOS has been the topic of several research analyst reports. Zacks Investment Research upgraded Glaukos Corporation from a “hold” rating to a “strong-buy” rating and set a $48.00 price objective on the stock in a research note on Tuesday, July 4th. BidaskClub downgraded Glaukos Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. Roth Capital decreased their target price on Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating on the stock in a research report on Thursday, August 3rd. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $56.00 target price on shares of Glaukos Corporation in a research report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. Glaukos Corporation has a consensus rating of “Buy” and a consensus target price of $48.57.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/11/01/glaukos-corporation-gkos-shares-bought-by-vanguard-group-inc.html.

In related news, Director Orbimed Advisors Llc sold 580,200 shares of Glaukos Corporation stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $38.73, for a total value of $22,471,146.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Thomas William Burns sold 1,212 shares of Glaukos Corporation stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $41.25, for a total transaction of $49,995.00. The disclosure for this sale can be found here. Insiders sold a total of 980,200 shares of company stock worth $37,900,263 in the last ninety days. 16.40% of the stock is currently owned by insiders.

Glaukos Corporation (NYSE:GKOS) opened at 35.31 on Wednesday. The firm’s market cap is $1.22 billion. Glaukos Corporation has a 52-week low of $28.72 and a 52-week high of $52.49. The stock has a 50 day moving average price of $33.66 and a 200 day moving average price of $33.88.

Glaukos Corporation Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Institutional Ownership by Quarter for Glaukos Corporation (NYSE:GKOS)

What are top analysts saying about Glaukos Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Glaukos Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit